Prasugrel Monotherapy After Percutaneous Coronary Intervention for Chronic Coronary Syndrome: Insights From ASET Pilot Studies [0.03%]
经皮冠状动脉介入治疗后慢性冠脉综合征的prasugrel单药治疗：来自ASET初步研究的启示
Shinichiro Masuda,Kengo Tanabe,Patricia O Guimarães et al.
Shinichiro Masuda et al.
Background: The ASET (Acetyl-Salicylic Elimination Trial) pilot studies recently investigated P2Y12 inhibitor monotherapy without aspirin immediately after percutaneous coronary intervention (PCI) in Brazil and Japan. ...
Heart Rate Fragmentation, Ambulatory Blood Pressure, and Coronary Artery Calcification: A Population-Based Study [0.03%]
心率离散、动态血压和冠状动脉钙化：一项人群基础的研究
Yuichi Sawayama,Yuichiro Yano,Takashi Hisamatsu et al.
Yuichi Sawayama et al.
Background: Little is known regarding whether ultra-rapid patterns of heart rate variability (eg, heart rate fragmentation [HRF]) are associated with coronary artery calcification (CAC) in a general population. ...
Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Role of Regional/Ethnic Differences: Focus on Asia [0.03%]
心力衰竭中钠-葡萄糖协同转运蛋白-2抑制剂的作用：区域/民族差异的作用：关注亚洲
Giulia Crisci,Andrea Salzano
Giulia Crisci
Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial [0.03%]
dapagliflozin对亚洲患者的影响：DELIVER试验的事后亚组分析
Xiaowen Wang,Carolyn S P Lam,Muthiah Vaduganathan et al.
Xiaowen Wang et al.
Background: Patients with heart failure (HF) with mildly reduced or preserved ejection fraction in Asia may have different clinical characteristics and outcomes compared with patients from other parts of the world. ...
Bleeding Risk in Asian Patients: Potential for Thrombin Amplification Pathway Blockade Using Factor XI Inhibitors [0.03%]
亚洲患者出血风险：使用XI因子抑制剂阻断凝血酶放大途径的潜力
Yan Liang,Qing Yang,Jun Zhu et al.
Yan Liang et al.
Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18 [0.03%]
亚洲患者使用Inclisiran的有效性和安全性：ORION-18研究结果
Yong Huo,Anastasia Lesogor,Cheol Whan Lee et al.
Yong Huo et al.
Background: Management of low-density lipoprotein cholesterol (LDL-C) in Asia remains suboptimal, with ∼50% of patients who are treated with lipid-lowering therapies (LLTs) unable to achieve their guideline-recommended L...
Unmasking the Hidden Risk: Atrial Fibrillation in Patients With Breast Cancer Treated With Aromatase Inhibitors [0.03%]
揭开隐藏的风险：接受芳香酶抑制剂治疗的乳腺癌患者中的房颤问题
Hidehira Fukaya
Hidehira Fukaya
Potential for Bridging Treatment Gaps in Cardiovascular Health in Asia With Inclusive Clinical Trials [0.03%]
通过包容性临床试验缩小亚洲心血管健康治疗差距的潜力
Aniruddh P Patel
Aniruddh P Patel
Beating-Heart Septal Myectomy: An Innovative Approach for Hypertrophic Obstructive Cardiomyopathy [0.03%]
跳动心脏室间隔肌切除术：肥厚性梗阻型心肌病的创新疗法
Liwen Liu,Jing Li
Liwen Liu
Shin-Huei Liu,Tze-Fan Chao
Shin-Huei Liu